Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tick-borne encephalitis virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Tick-borne encephalitis virus. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-001348-31 Sponsor Protocol Number: 2011-001348-31 Start Date*: 2011-05-31
    Sponsor Name:Mälarsjukhuset
    Full Title: Can the dosage of vaccine against TBE is optimized by means of changes in dosing interval for those over 50 years
    Medical condition: Tick-borne Encephalitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10043848 Tick-borne viral encephalitis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000440-27 Sponsor Protocol Number: 690701 Start Date*: Information not available in EudraCT
    Sponsor Name:Baxter AG
    Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
    Medical condition: In this Study the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies after the First Booster and the Response to a Second Booster Vaccination with FSME-IMMUN 0.5ml in Adults will be ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020097-42 Sponsor Protocol Number: 701001 Start Date*: 2010-08-03
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years
    Medical condition: Evaluation of Immunogenicity of a TBE (Tick Borne Encephalitis) Vaccine in previously unvaccinated children aged 1 to below 15 years
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000810-35 Sponsor Protocol Number: TBE-Ped-Accel-01 Start Date*: 2007-04-19
    Sponsor Name:BIOVOMED
    Full Title: Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25 ml JUNIOR in Healthy Children aged 3 - 15 Years
    Medical condition: Prevention of Tick-born encephalitis (TBE). The rapid immunization schedule recommended in the current SPC for FSME-IMMUN 0.5 ml (Day 0, Day 14) has been used in Austria for 20 years. FSME-IMMUN 0....
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001676-21 Sponsor Protocol Number: V48P7E1 Start Date*: 2006-08-14
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants...
    Medical condition: TBE prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-002691-10 Sponsor Protocol Number: 700801 Start Date*: 2008-08-28
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Single-Blind, randomized, Phase III B Study in children aged 1-11 years to investigate the immunogenicity, safety and interchangeability of two tick-borne encephalitis (TBE) vaccines administered a...
    Medical condition: assess the immunogenicity, safety and interchangeability of two tick-borne encephalitis (TBE) vaccines in children aged 1-11 years
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-009324-36 Sponsor Protocol Number: B9371021_(Formerly_Baxter_700802) Start Date*: 2009-03-04
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
    Medical condition: Active (prophylactic) immunization against TBE The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the fi...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10043847 Tick-borne viral encephalitis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004674-94 Sponsor Protocol Number: WI237607 Start Date*: 2019-04-05
    Sponsor Name:Riga Stradiņš University
    Full Title: Open-label Phase IV Study to Investigate Broad-and Cross-neutralizing Antibodies after Primary Vaccination with Two Different TBE Vaccines
    Medical condition: Active (prophylactic) immunization against tick-borne encephalitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043847 Tick-borne viral encephalitis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002928-41 Sponsor Protocol Number: Immunity_TBE Start Date*: 2013-01-14
    Sponsor Name:Med. Uni. Wien, Klinik für Innere I
    Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
    Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-004181-37 Sponsor Protocol Number: B9371039 Start Date*: 2023-02-03
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER
    Medical condition: Active immunization to prevent tick borne encephalitis (TBE)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000801-61 Sponsor Protocol Number: ITM201901 Start Date*: 2019-05-09
    Sponsor Name:Institute of Tropical Medicine Antwerp
    Full Title: Toward an optimal accelerated Tick-Borne Encephalitis (TBE) vaccination schedule for the last-minute traveler
    Medical condition: Thick-Borne Encephalitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005645-38 Sponsor Protocol Number: TBEB08 Start Date*: 2008-01-17
    Sponsor Name:Clinical Institute of Virology, Medical University of Vienna
    Full Title: B-cell memory and humoral immune response after primary immunization against tick borne encephalitis (TBE) in the elderly
    Medical condition: This study will investigate immunity against tick-borne encephalitis (TBE) following primary TBE vaccination in healthy volunteers 18-30 years or > 60 years who fulfill the local criteria for TBE v...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036897 Prophylactic vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005105-20 Sponsor Protocol Number: V48P4E3 Start Date*: 2014-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: Evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-de...
    Medical condition: Prophylaxis: Tick-borne-encephalitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003255-19 Sponsor Protocol Number: V48P7E2 Start Date*: 2011-10-06
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 10 years after the first booster immunization with Tick Borne Encephalitis vaccine in adults who received 1 of...
    Medical condition: No medical condition, healthy subjects.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-004366-34 Sponsor Protocol Number: 311_FU2013 Start Date*: 2013-12-13
    Sponsor Name:Medizinische Universität Wien
    Full Title: Neutralizing Antibody Titers 6 Years after the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection
    Medical condition: Study population: adult volunteers who received a booster dose of JE-VC in prestudy IC51-311, no specific medical condition is investigated, only antibody check.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001356-59 Sponsor Protocol Number: 205847 Start Date*: 2017-09-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 15 years after the first booster immunization with Encepur Adults (Polygeline-free Tick-borne Encephalitis vac...
    Medical condition: Healthy volunteers (Active immunization in individuals from 12 years of age against tick-borne encephalitis (TBE) virus. The vaccination is intended for residents or travellers in TBE-endemic areas...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-000768-19 Sponsor Protocol Number: 700501 Start Date*: 2005-08-02
    Sponsor Name:Baxter Vaccine AG
    Full Title: Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approximately 3 Years after a Booster Vaccination with FSME-IMMUN 0.25 ml Junior in Children
    Medical condition: Tick-borne encephalitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002647-27 Sponsor Protocol Number: 092004 Start Date*: 2005-03-10
    Sponsor Name:Universitätsklinik für Kinder-und Jugendheilkunde
    Full Title: FSME (human tick-borne encephalitis) - vaccination in children after thymectomy
    Medical condition: In children who undergo open heart surgery because of heart vitium, for surgical reasons the thymus has to be removed. If thymectomy in early childhood alters the function of the immunsystem has be...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015595-10 Sponsor Protocol Number: IC51-322 Start Date*: 2010-03-23
    Sponsor Name:Intercell AG
    Full Title: IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®, JESPECT®) IN A PEDIATRIC POPULATION IN NON‐ENDEMIC COUNTRIES. UNCONTROLLED, OPEN‐LABEL PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003786-41 Sponsor Protocol Number: V70P5 Start Date*: 2007-10-22
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vacci...
    Medical condition: no medical, condition: healthy,
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) IT (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 17:47:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA